PuSH - Publikationsserver des Helmholtz Zentrums München

Carlet, M. ; Schmelz, K.* ; Vergalli, J. ; Herold, T. ; Senft, D. ; Jurinovic, V. ; Hoffmann, T.* ; Proba, J.* ; Weichert, N.* ; Junghanß, C.* ; Roth, M.* ; Eschenburg, G.* ; Barz, M.* ; Henze, G.* ; Eckert, C.* ; Eggert, A.* ; Zuber, J.* ; Hundsdoerfer, P.* ; Jeremias, I.

X-linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory ALL.

EMBO Mol. Med.:e14557 (2022)
Verlagsversion Forschungsdaten DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Acute lymphoblastic leukemia (ALL) represents the most frequent malignancy in children, and relapse/refractory (r/r) disease is difficult to treat, both in children and adults. In search for novel treatment options against r/r ALL, we studied inhibitor of apoptosis proteins (IAP) and Smac mimetics (SM). SM-sensitized r/r ALL cells towards conventional chemotherapy, even upon resistance against SM alone. The combination of SM and chemotherapy-induced cell death via caspases and PARP, but independent from cIAP-1/2, RIPK1, TNFα or NF-κB. Instead, XIAP was identified to mediate SM effects. Molecular manipulation of XIAP in vivo using microRNA-30 flanked shRNA expression in cell lines and patient-derived xenograft (PDX) models of r/r ALL mimicked SM effects and intermediate XIAP knockdown-sensitized r/r ALL cells towards chemotherapy-induced apoptosis. Interestingly, upon strong XIAP knockdown, PDX r/r ALL cells were outcompeted in vivo, even in the absence of chemotherapy. Our results indicate a yet unknown essential function of XIAP in r/r ALL and reveal XIAP as a promising therapeutic target for r/r ALL.
Impact Factor
Scopus SNIP
Altmetric
14.260
2.152
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Pdx ; Relapsed/refractory Acute Lymphoblastic Leukemia ; Smac Mimetics ; Therapeutic Target ; Xiap
Sprache englisch
Veröffentlichungsjahr 2022
HGF-Berichtsjahr 2022
ISSN (print) / ISBN 1757-4676
e-ISSN 1757-4684
Quellenangaben Band: , Heft: , Seiten: , Artikelnummer: e14557 Supplement: ,
Verlag Wiley
Verlagsort Chichester
Begutachtungsstatus Peer reviewed
Institut(e) Research Unit Apoptosis in Hematopoietic Stem Cells (AHS)
POF Topic(s) 30204 - Cell Programming and Repair
Forschungsfeld(er) Stem Cell and Neuroscience
PSP-Element(e) G-506600-001
Förderungen Helmholtz Zentrum Munchen
Deutsche Krebshilfe
José Carreras Leukämie-Stiftung
Deutsche Forschungsgemeinschaft
European Research Council
Bettina Bräu Stiftung and Dr. Helmut Legerlotz Stiftung
Berliner Krebsgesellschaft
Scopus ID 85142513998
PubMed ID 36416169
Erfassungsdatum 2022-12-08